Is Trident Lifeline overvalued or undervalued?

As of 14 October 2025, Trident Lifeline's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its valuation outlook. The company is currently deemed overvalued. Key ratios include a PE ratio of 21.14, an EV to EBITDA of 17.87, and a ROE of 9.87%.
When compared to peers, Trident Lifeline's PE ratio is significantly lower than Sun Pharma's 34.56 and Divi's Lab's 75.47, both categorized as very expensive. In contrast, it is higher than Dr. Reddy's Labs, which boasts a PE of 18.18 and is classified as very attractive. Additionally, Trident's PEG ratio of 0.25 suggests potential growth at a reasonable price, but overall, the company's current valuation does not justify its price relative to its peers. Notably, while Trident's stock has outperformed the Sensex over a three-year period, its recent one-week performance has lagged behind the index.